Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its prospectus dated June 16, 2023, with details from its quarterly report filed on May 15, 2024. The supplement relates to the issuance of 2,270,000 shares of common stock, Class A and B Common Warrants to purchase up to 2,270,000 shares of common stock each, Pre-Funded Warrants to purchase up to 2,270,000 shares of common stock, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.4408 per share as of May 14, 2024. The supplement, which includes the Quarterly Report, provides updated financial information and risk factors for investors, highlighting the company...Show More

Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its prospectus dated June 16, 2023, with details from its quarterly report filed on May 15, 2024. The supplement relates to the issuance of 2,270,000 shares of common stock, Class A and B Common Warrants to purchase up to 2,270,000 shares of common stock each, Pre-Funded Warrants to purchase up to 2,270,000 shares of common stock, and up to 6,810,000 shares of common stock underlying the warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.4408 per share as of May 14, 2024. The supplement, which includes the Quarterly Report, provides updated financial information and risk factors for investors, highlighting the company's high degree of risk due to its involvement in securities. Panbela Therapeutics, Inc., a Delaware corporation with principal executive offices in Minnesota, has been subject to filing requirements and has submitted all required reports. The company's financial statements reveal a net loss of $7,120,000 for the quarter ended March 31, 2024, and an accumulated deficit of $132,617,000. The company has faced challenges including a notice from Nasdaq regarding the delisting of its common stock due to non-compliance with the minimum stockholders' equity requirement.